Ankylosing Spondylitis and Ulcerative Colitis
Links shared publicly online about this topic
FDA accepts NDA for Vimovo for treatment of arthritis and ankylosing spondylitis - MPR
empr.com — “Pozen announced that a New Drug Application (NDA) for Vimovo (formerly PN 400), a fixed-dose combination tablet containing enteric-coated naproxen and immediate-release esomeprazole, has been filed and accepted for review by the FDA for the treatment of the signs and symptoms of osteoarthritis (OA), rheumatoid arthritis (RA), and ankylosing spondylitis (AS) in patients who are at risk of developing non-steroidal anti-inflammatory drug (NSAID) associated gastric ulcers.” View full resource at empr.com
Most Recently Shared on August 31, 2009 at 6:24 pm By:
MPR News: FDA accepts NDA for Vimovo for treatment of arthritis and ankylosing spondylitis: Pozen annou.. http://bit.ly/1cBz3g
FDA Approved Vimovo for Arthritis Patients At Risk of Developing NSAID-Associated Gastric Ulcers
drugs.com — “Vimovo (naproxen and esomeprazole magnesium) is used for the relief of signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, and to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers. Includes Vimovo side effects, interactions and indications.” View full resource at drugs.com
Most Recently Shared on May 3, 2010 at 11:27 pm By:
FDA Approved Vimovo for Arthritis Patients At Risk of Developing NSAID-Associated Gastric Ulcers - http://bit.ly/97LKEK
REMICADE (infliximab) - Indication and Safety Information
remicade.com — “REMICADE" (infliximab) is currently indicated for rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and psoriatic arthritis.” View full resource at remicade.com
Most Recently Shared on April 22, 2010 at 4:04 pm By:
Susan Scroggins Active Health Library and Health Advocate
Considering Remicade? Learn why Remicade may be indicated and safety concerns associated with the medication. http://bit.ly/cDU7A3
FDA Approved VIMOVO(TM) For Arthritis Patients At Risk Of Developing NSAID-Associated Gastric Ulcers
medicalnewstoday.com — “AstraZeneca and POZEN Inc. announced the U.S. Food and Drug Administration (FDA) has approved VIMOVO™ (naproxen and esomeprazole magnesium) delayed-release tablets for the relief of signs an” View full resource at medicalnewstoday.com
Most Recently Shared on May 1, 2010 at 2:06 pm By:
MNT Gastrointestinal Health News
FDA Approved VIMOVO(TM) For Arthritis Patients At Risk Of Developing NSAID-Associated Gastric Ulcers http://mnt.to/3C2P #gastrointestinal
VIMOVO - New Product Releases - MPR
empr.com — “Osteoarthritis, rheumatoid arthritis, ankylosing spondylitis: to improve symptoms and reduce risk of gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers.” View full resource at empr.com
Most Recently Shared on August 13, 2010 at 1:10 pm By:
MPR News: VIMOVO: Naproxen 375mg + esomeprazole (as magnesium trihydrate) 20mg; naproxen 500mg + esomeprazole (as ... http://bit.ly/9ra5yY
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Featuring the top 3 experts for this topic
-
MPR
eMPR.com provides up-to-date, concise drug information at the point-of-care.
-
Drugs.com
Keeping you up to date with the latest medication news, FDA Medwatch alerts and new drug approvals.
-
Susan Scroggins
Passionate about sharing quality health resources for good health. Content curator and organizer at organizedwisdom.com.
Advertisement
